BCL2AETooL
Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies

Released: August 23, 2024

Expiration: August 22, 2025

About This Tool & Disclaimer

Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies

Clinical Care Options, LLC, is grateful to Farrukh Awan, MD, MS, MBA; Courtney DiNardo, MD, MSCE; Daniel A. Pollyea, MD, MS; and Caitlin R. Rausch, PharmD, BCOP, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in August 2024 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on optimal strategies to minimize and manage toxicity with BCL-2 inhibitor therapy.

A series of questions allow the user to select individual patient characteristics that are necessary to know before making recommendations on adverse event (AE) management. These characteristics include the type of malignancy, current AE, and severity.

It should be noted that these are not exclusive characteristics when recommending management strategies for patients with AEs on BCL-2 inhibitor therapy. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered, when appropriate for making management decisions.

This tool assumes we have a “standard” patient with CLL/SLL or AML and is currently receiving or planning to start BCL-2 inhibitor therapy, but has no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display guideline-based recommendations for that specific patient case and selected AE.

For additional information on best practices in the management of AEs with BCL-2 inhibitor therapy, see our online program titled, “Expert Management of Treatment-Related Symptoms From BCL-2 Inhibitors

© 2024 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on optimal management choices for adverse events associated with BCL-2 inhibitor therapy in AML, CLL, or SLL. The information provided is based on NCCN guideline recommendations, prescribing information for venetoclax, and expert guidance from Farrukh Awan, MD, MS, MBA; Courtney DiNardo, MD, MSCE; Daniel A. Pollyea, MD, MS; and Caitlin R. Rausch, PharmD, BCOP.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Tool for Managing Adverse Events Associated With BCL-2 Inhibitors in Hematologic Malignancies” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content